ENDRA Life Sciences Inc. (NDRA) Q2 2023 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Endra Life Sciences Inc..

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.029 -- 00:00:05.934 Good day and welcome to the Enduro Life Sciences second quarter 2023 00:00:05.934 -- 00:00:11.299 financial results conference call. All participants will be in listen-only mode. 00:00:11.299 -- 00:00:15.002 Should you need assistance, please signal a conference specialist by pressing the star 00:00:15.002 -- 00:00:18.365 key then zero on your telephone keypad. 00:00:18.365 -- 00:00:22.549 After today's presentation, there will be an opportunity to ask questions. 00:00:22.549 -- 00:00:27.699 To ask a question, you may press star then one on your telephone keypad. 00:00:27.699 -- 00:00:31.200 To withdraw your question, please press star then 2. 00:00:31.200 -- 00:00:35.542 Please note this event is being recorded. I would now like to turn the conference over 00:00:35.542 -- 00:00:38.583 to Yvonne Briggs. Please go ahead. 00:00:38.583 -- 00:00:41.944 Thank you, operator. This is Yvonne Briggs with LHA. 00:00:41.944 -- 00:00:46.526 Good afternoon and welcome to NDRA's second quarter 2023 business update and financial 00:00:46.526 -- 00:00:51.877 results conference call. Earlier today, NDRA issued a press release on this topic. 00:00:51.877 -- 00:00:56.278 and also issued a news release announcing the submission of a de novo request for its 00:00:56.278 -- 00:01:01.339 TAIS system to the U.S. FDA, both of which are available in the investor section 00:01:01.339 -- 00:01:06.240 of NDRA's website. Before we begin, please note that today's discussion will include 00:01:06.240 -- 00:01:11.661 forward-looking statements. All statements by management other than statements of historical 00:01:11.661 -- 00:01:17.482 facts include statements regarding the company's strategies, financial condition, operations, 00:01:17.482 -- 00:01:23.245 costs,...